Risikoen for udvikling af influenzavira med nedsat følsomhed eller reel resistens over for oseltamivir er blevet undersøgt gennem Roche- sponsorerede kliniske studier.
The risk of emergence of influenza viruses with reduced susceptibility or frank resistance to oseltamivir has been examined during Roche-sponsored clinical studies.